Published in Gut on July 21, 2010
Trial of Ketotifen in Children and Adolescents (Ketotifen) | NCT02484248
Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30
Increase of colonic mast cells in obstructed defecation and their relationship with enteric glia. Dig Dis Sci (2011) 2.02
Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol (2011) 1.89
Randomised controlled trial of mesalazine in IBS. Gut (2014) 1.58
A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut (2015) 1.55
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
Mast cells and intestinal motility disorders (mastocytic enteritis/colitis). Dig Dis Sci (2012) 1.44
Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. Am J Physiol Gastrointest Liver Physiol (2011) 1.38
Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol (2011) 1.15
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.14
Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil (2012) 1.14
Irritable bowel syndrome - An inflammatory disease involving mast cells. Asia Pac Allergy (2011) 1.09
Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity. Brain Behav Immun (2011) 1.08
An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil (2012) 1.07
Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr (2012) 0.96
Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr (2016) 0.94
Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. Gut (2013) 0.92
IBS and the role of otilonium bromide. Int J Colorectal Dis (2012) 0.89
Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.88
IBS in 2010: advances in pathophysiology, diagnosis and treatment. Nat Rev Gastroenterol Hepatol (2011) 0.88
Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders. Aliment Pharmacol Ther (2015) 0.87
Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS One (2013) 0.86
Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia. World J Gastrointest Pharmacol Ther (2013) 0.86
Neuroanatomy of lower gastrointestinal pain disorders. World J Gastroenterol (2014) 0.85
Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol (2015) 0.84
Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol (2014) 0.83
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest (2013) 0.83
Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside. J Neurogastroenterol Motil (2016) 0.83
Protease-activated receptors as therapeutic targets in visceral pain. Curr Neuropharmacol (2013) 0.82
Lessons Learnt from Post-Infectious IBS. Front Physiol (2011) 0.82
The role of colonic mast cells and myenteric plexitis in patients with diverticular disease. Int J Colorectal Dis (2012) 0.80
Mast Cell-Mediated Mechanisms of Nociception. Int J Mol Sci (2015) 0.80
Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol (2011) 0.80
Essential role of mast cells in the visceral hyperalgesia induced by T. spiralis infection and stress in rats. Mediators Inflamm (2012) 0.80
Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significance. Int J Clin Exp Pathol (2014) 0.79
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial. Trials (2013) 0.79
The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil (2016) 0.79
Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonists. PLoS One (2013) 0.79
IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol (2016) 0.79
Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol (2016) 0.79
Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome. Evid Based Complement Alternat Med (2016) 0.78
Mast Cell-dependent Mesenteric Afferent Activation by Mucosal Supernatant From Different Bowel Segments of Guinea Pigs With Post-infectious Irritable Bowel Syndrome. J Neurogastroenterol Motil (2015) 0.78
Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review. Therap Adv Gastroenterol (2015) 0.78
Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol (2014) 0.78
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
Functional Gastrointestinal Symptoms Are Associated with Higher Serum Total IgE Levels, but Less Atopic Sensitization. Dig Dis Sci (2015) 0.77
The Expression of Serum Antibodies Against Gonadotropin-releasing Hormone (GnRH1), Progonadoliberin-2, Luteinizing Hormone (LH), and Related Receptors in Patients with Gastrointestinal Dysfunction or Diabetes Mellitus. Drug Target Insights (2014) 0.76
Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea. Am J Physiol Gastrointest Liver Physiol (2016) 0.76
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
Mast Cell Stabilizer (Ketotifen) in Fibromyalgia: Phase 1 Randomized Controlled Clinical Trial. Clin J Pain (2014) 0.76
Dose Irritable Bowel Syndrome and Dysmotility Have an Autoimmune Origin? (Neurogastroenterol Motil 2011;23:1000-1006, e459). J Neurogastroenterol Motil (2012) 0.75
The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract (2016) 0.75
Changes in mast cell infiltration: a possible mechanism in detrusor overactivity induced by visceral hypersensitivity. Int Braz J Urol (2016) 0.75
Increased VGLUT3 involved in visceral hyperalgesia in a rat model of irritable bowel syndrome. World J Gastroenterol (2015) 0.75
Possible therapeutic role of IgE blockade in irritable bowel syndrome. World J Gastroenterol (2016) 0.75
Evaluating the Anti-nociceptive and Anti-inflammatory Effects of Ketotifen and Fexofenadine in Rats. Adv Pharm Bull (2015) 0.75
Mechanism-Oriented Therapy of Irritable Bowel Syndrome. Adv Ther (2016) 0.75
Word of caution before implementing ketotifen for gastrointestinal transit improvement. World J Gastroenterol (2013) 0.75
Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications. Clujul Med (2014) 0.75
Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview. Pharmacology (2015) 0.75
Esophageal Mast Cell Infiltration in a 32-Year-Old Woman with Noncardiac Chest Pain. Gut Liver (2016) 0.75
Therapeutic potential of ketotifen in irritable bowel syndrome (IBS) may involve changes in mast cells at sites beyond the rectum. Gut (2010) 0.75
Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol Motil (2016) 0.75
Is irritable bowel syndrome a rhinitis of the gut? Gastroenterology (2011) 0.75
The antinociception of oxytocin on colonic hypersensitivity in rats was mediated by inhibition of mast cell degranulation via Ca(2+)-NOS pathway. Sci Rep (2016) 0.75
Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study. United European Gastroenterol J (2017) 0.75
Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. J Neurogastroenterol Motil (2017) 0.75
Early weaning stress induces chronic functional diarrhea, intestinal barrier defects, and increased mast cell activity in a porcine model of early life adversity. Neurogastroenterol Motil (2017) 0.75
Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. Gastroenterology (2017) 0.75
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol (2005) 4.91
Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology (2012) 3.90
Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology (2009) 3.67
Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology (2012) 3.35
The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut (2009) 2.72
An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol (2013) 2.43
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A (2007) 2.27
Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology (2007) 2.22
Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol (2008) 2.16
Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship? Am J Gastroenterol (2012) 2.16
Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity. Nat Commun (2013) 2.08
Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology (2011) 1.96
Basophil activation test in the diagnosis and monitoring of mastocytosis patients with wasp venom allergy on immunotherapy. Cytometry B Clin Cytom (2014) 1.94
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr (2008) 1.78
Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon. Gastroenterology (2006) 1.66
Irritable bowel syndrome--the main recommendations. Dtsch Arztebl Int (2011) 1.56
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology (2009) 1.50
Postoperative ileus is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice. Gastroenterology (2003) 1.43
Markers of Bone Metabolism in Obese Individuals Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg (2015) 1.41
Environmental exposure reduction in high-risk newborns: where do we start? Ann Allergy Asthma Immunol (2003) 1.39
Management of achalasia: surgery or pneumatic dilation. Gut (2011) 1.33
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res (2011) 1.29
Mast cell-nerve axis with a focus on the human gut. Biochim Biophys Acta (2011) 1.22
A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. Gut (2013) 1.20
Role of enteric glia in intestinal physiology: effects of the gliotoxin fluorocitrate on motor and secretory function. Am J Physiol Gastrointest Liver Physiol (2006) 1.19
Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem (2010) 1.17
Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. Gastroenterology (2009) 1.16
Vesicle associated membrane protein (VAMP)-7 and VAMP-8, but not VAMP-2 or VAMP-3, are required for activation-induced degranulation of mature human mast cells. Eur J Immunol (2008) 1.15
Diet-induced obesity has neuroprotective effects in murine gastric enteric nervous system: involvement of leptin and glial cell line-derived neurotrophic factor. J Physiol (2011) 1.14
The vagal innervation of the gut and immune homeostasis. Gut (2012) 1.12
Cutting-edge technology. III. Imaging and the gastrointestinal tract: mapping the human enteric nervous system. Am J Physiol Gastrointest Liver Physiol (2002) 1.10
Depletion of the colonic epithelial precursor cell compartment upon conditional activation of the hedgehog pathway. Gastroenterology (2009) 1.10
Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr (2011) 1.09
Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol (2007) 1.08
Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest (2012) 1.07
Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology (2004) 1.06
Symptomatology, pathophysiology, diagnostic work-up, and treatment of Hirschsprung disease in infancy and childhood. Curr Gastroenterol Rep (2007) 1.06
Bacterial proteases in IBD and IBS. Gut (2011) 1.05
Functional expression of the peptide transporter PEPT2 in the mammalian enteric nervous system. J Comp Neurol (2005) 1.05
Quantitative assessment of glial cells in the human and guinea pig enteric nervous system with an anti-Sox8/9/10 antibody. J Comp Neurol (2008) 1.04
Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis (2009) 1.04
Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus. J Biol Chem (2003) 1.04
Multifunctional rapidly adapting mechanosensitive enteric neurons (RAMEN) in the myenteric plexus of the guinea pig ileum. J Physiol (2009) 1.04
Role of activator protein 1, nuclear factor-kappaB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J Allergy Clin Immunol (2003) 1.04
Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci (2012) 1.03
The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest (2002) 1.03
Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors. Gastroenterology (2005) 1.02
Pre- and postoperative nutritional deficiencies in obese patients undergoing laparoscopic sleeve gastrectomy. Obes Surg (2012) 1.02
Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br J Pharmacol (2010) 1.02
New therapeutic strategies for postoperative ileus. Nat Rev Gastroenterol Hepatol (2012) 1.01
Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One (2013) 1.01
Exposure to severe wartime conditions in early life is associated with an increased risk of irritable bowel syndrome: a population-based cohort study. Am J Gastroenterol (2009) 1.01
The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol (2009) 1.00
Achalasia: virus-induced euthanasia of neurons? Am J Gastroenterol (2008) 1.00
Validation of gastric-emptying scintigraphy of solids and liquids in mice using dedicated animal pinhole scintigraphy. J Nucl Med (2003) 0.99
Effect of glutamine-enriched total parenteral nutrition in patients with acute pancreatitis. Clin Nutr (2002) 0.98
Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res (2010) 0.97
Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem (2012) 0.97
Development and validation of challenge materials for double-blind, placebo-controlled food challenges in children. J Allergy Clin Immunol (2004) 0.96
Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal (2011) 0.96
GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol (2010) 0.96
SNAP-23 and syntaxin-3 are required for chemokine release by mature human mast cells. Mol Immunol (2011) 0.96
IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. J Immunol (2005) 0.95
Mechanosensitive enteric neurons in the myenteric plexus of the mouse intestine. PLoS One (2012) 0.95
Ruminal muscle of sheep is innervated by non-polarized pathways of cholinergic and nitrergic myenteric neurones. Cell Tissue Res (2002) 0.94
Micronutrient deficiency in obese subjects undergoing low calorie diet. Nutr J (2012) 0.94
The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease. Expert Rev Gastroenterol Hepatol (2010) 0.94
Intestinal mast cells in gut inflammation and motility disturbances. Biochim Biophys Acta (2011) 0.93
A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study. Eur J Nutr (2012) 0.92
The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice. Br J Pharmacol (2005) 0.92
Properties of myenteric neurones and mucosal functions in the distal colon of diet-induced obese mice. J Physiol (2013) 0.92
Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. Vet Immunol Immunopathol (2006) 0.91
Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J Immunol (2004) 0.91
Is 30 minutes between doses long enough in oral food challenges? Pediatr Allergy Immunol (2014) 0.90
Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Understanding the reward system functioning in anorexia nervosa: crucial role of physical activity. Biol Psychol (2013) 0.90
Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells. Lab Invest (2011) 0.90
Management of achalasia. Gastroenterol Clin North Am (2012) 0.90
Isolation, culture, and characterization of intestinal mast cells. Methods Mol Biol (2006) 0.89
Exposure, sensitization, and mechanisms of fungus-induced asthma. Curr Allergy Asthma Rep (2003) 0.89
Enteric nervous system. Curr Opin Gastroenterol (2005) 0.89
Reticular groove and reticulum are innervated by myenteric neurons with different neurochemical codes. Anat Rec A Discov Mol Cell Evol Biol (2003) 0.89
Neuronal cGMP kinase I is essential for stimulation of duodenal bicarbonate secretion by luminal acid. FASEB J (2012) 0.88
Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology (2007) 0.88
Analysis of the intestinal microbiota using SOLiD 16S rRNA gene sequencing and SOLiD shotgun sequencing. BMC Genomics (2013) 0.88
Recordings from human myenteric neurons using voltage-sensitive dyes. J Neurosci Methods (2010) 0.87
Enteric nervous system. Curr Opin Gastroenterol (2006) 0.87